BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California. Show more

1445A South 50th Street, Richmond, CA, 94804, United States

Drug Manufacturers - Specialty & Generic

Healthcare

Start AI Chat

Market Cap

891.4M

52 Wk Range

$2.88 - $24.00

Previous Close

$21.35

Open

$21.50

Volume

311,921

Day Range

$21.00 - $21.83

Enterprise Value

-77.03M

Cash

285.8M

Avg Qtr Burn

-16.04M

Insider Ownership

2.56%

Institutional Own.

63.72%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BGE-102 (NLRP3 Inhibitor) Details Diabetic Macular Edema	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BGE-102 Details Obesity	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.